Headquartered in Shanghai, China, Vcell
healthcare is a biotech company focused on the development, manufacturing and
commercialization of advanced mAb biosimilars in China, with a commitment of bringing
affordable world-class biological therapeutics to Chinese patients. It is a
joint venture established in 2019 by Celltrion, a leading biopharmaceutical
company which has developed world's first mAb biosimilar that has received US
FDA/EMA approval, and Nan Fung Group, a renowned conglomerate based in Hong
Kong. Vcell has in-licensed several US FDA and EMA approved biosimilar products
from Celltrion, including Remsima®,Truxima® and Herzuma®,
all have been proven their efficacy and safety through multiple global clinical trials.
Remsima® (infliximab biosimilar) is the world's
first mAb biosimilar developed by Celltrion and is a therapeutic agent for
autoimmune diseases with including rheumatoid arthritis and ankylosing
spondylitis. Remsima® has become one of the bestselling biosimilars worldwide
and already secured over 50% of the European market thanks to its advantages
such as broad indications among TNF-α inhibitor products, equivalent efficacy
and safety to the original drug product, and reasonable price. Remsima® received marketing authorization approval from the European EMA and the US FDA,
and, in total, has been launched in over 80 countries. Remsima® is now undergoing phase III clinical
trial in China.
Truxima® (rituximab biosimilar) is the world's first
mAb biosimilar in oncology used in the treatment of non-Hodgkin's lymphoma and
rheumatoid arthritis. Truxima® has received regulatory approval in Europe and
US. It has been launched in Europe since 2017 and gained over 27% market share
within a year of entry, and 36% market share in 2018.
Herzuma® (trastuzumab biosimilar) is
an anticancer mAb biosimilar used to treat HER2+ breast cancer and gastric cancer that
has been proven through multiple global clinical trials. Herzuma® is an effective, more
affordable alternative to biologics for the treatment of breast cancer and gastric
cancer, and has received regulatory approval in over 40 countries including
Europe, US and Japan.